Kornimate/medical-research-clean huggingface dataset:
evaluation of three non-invasive analgesic techniques in pain prevention during injections

Conditions: Injection Pain Prevention

Summary: injections are associated to a certain level of pain which tolerance can vary between individuals. as regards non-invasive pain control techniques in subcutaneous injections, scarce literature exists with adequate levels of evidence and design quality to support any specific analgesic method. in this study, the investigators evaluated the effectivity of three non-invasive analgesic techniques (cold, anesthetic cream and vibration) when performing subcutaneous forehead injections, in a series of 100 healthy volunteers.

this study is a randomized, controlled, simple-blind clinical trial, and it has been approved by the ethics committee of the medical research institute hospital la fe. the study included 100 healthy volunteered, and it was performed in the university and polytechnic hospital la fe, valencia. the procedures of the study consisted in the sequential performance of four injections of 0,1ml of physiologic saline (0,9%nacl) in the forehead of each subject, 2cm above the eyebrows, with a 29g needle, after applying any of the non-invasive anesthetic methods studied in the trial, except for the control zone. the anesthetic method utilized in each part of the forehead of each patient was randomized through simple randomization. injections always started from the right side of the forehead to the left. the non-invasive analgesic methods utilized were: * control zone: none * vibration: application of the vibrating device on the skin below the injection site, before and during injection. * cold: application of a bag of 50ml of frozen physiologic saline covered with a plastic glove on the injection site for 50 seconds prior to performing the injection. * anesthetic cream: application of a uniform thickness of 2mm of the anesthetic cream emla covered with an adhesive transparent plastic dressing for 30 minutes, before injection.

Eligibility criteria:
inclusion criteria: * every subject who did not meet any of the exclusion criteria, and signed the informed consent, was included in the study exclusion criteria: * subjects younger than 18 * subjects that suffered from any local or systemic sensitivity alteration * subjects that suffered from any cognitive deficit * individuals allergic to any of the components of the anesthetic ointment emla (eutectic mixture of lidocaine 2,5% and prilocaine 2,5%).

Keywords: analgesia cryoanalgesia vibration analgesia local anesthetic
evaluating the impact of baduanjin exercise intervention on quality of life in breast cancer survivors receiving aromatase inhibitor therapy

Conditions: Breast Cancer Survivors Receiving Aromatase Inhibitor Therapy

Summary: a 12-week randomized controlled trail was conducted in 72 chinese breast cancer survivors who had received aromatase inhibitors treatment for more than 6 months. all participants were assigned to either 12 weeks of baduanjin classes which involved to two 90-minute sessions per week or a wait-list control. participants completed fitness assessments, measurements of lipopolysaccharide-stimulated production of proinﬂammatory cytokines interleukin-6 (il-6), tumor necrosis factor alpha (tnf-α), interleukin-1β(il-1β) ,c-reactive protein (crp) ，bmi，bmd and questionnaires to measure qol, fatigue, sleep quality, aromatase inhibitor-induced arthralgia, symptoms of climacteric syndrome were completed at baseline and 3 months.


Eligibility criteria:
inclusion criteria: * have been diagnosed as stage i to iii breast cancer 0.5 to 4.0 years before enrollment * taking an ai (aromatase inhibitors )，and had been receiving an ai for at least 6 months exclusion criteria: * a prior history of breast or any other cancer except basal or squamous cell skin cancer inﬂammatory breast cancer * with exercise contraindications：chronic obstructive pulmonary disease, uncontrolled hypertension, evidence of liver or kidney failure, symptomatic ischemic heart disease ,conditions involving the immune system such as autoimmune and/or inﬂammatory diseases, cognitive impairment, alcohol/drug abuse * current baduanjin practice (within the last 6 months), and/or previous baduanjin practice for more than 3 months * women reporting 5 hours or more of vigorous physical activity per week

Keywords: breast cancer aromatase inhibitor therapy baduanjin exercise
psychiatric and cognitive manifestations of parkinson's disease

Conditions: Parkinson's Disease

Summary: parkinson's disease (pd) is often thought of as affecting movement only. in fact, most patients also experience psychiatric and cognitive symptoms, sometimes from the disease itself, and sometimes as a side-effect of pd medications. the goals of this study are to evaluate the causes, effects, and clinical correlates of psychiatric and cognitive symptoms in pd.

parkinson's disease (pd) is defined by the presence of motor symptoms, but in recent years there has been increasing recognition of non-motor manifestations, including anxiety, depression, and cognitive symptoms. in addition, pd medications have been shown to cause impulse control disorders, cognitive changes, and non-motor withdrawal symptoms (dopamine agonist withdrawal syndrome) when they are discontinued. the goals of this study are to test the hypothesis that the presence of psychiatric and cognitive symptoms are associated with greater self-perceived disability (out of proportion to objective deficits), increased utilization of healthcare resources, and decreased quality of life. in addition, we will examine the clinical correlates of these psychiatric symptoms. to test these hypotheses, we will screen pd patients for anxiety, depression, impulse control disorders, and dopamine agonist withdrawal syndrome, and compare cases and controls with regard to demographic characteristics, motor features of pd, disability, healthcare utilization, and quality of life.

Eligibility criteria:
inclusion criteria: * diagnosis of idiopathic parkinson's disease (or healthy control subject) * age \>=21 and \<=99 * capacity to provide informed consent * ability to complete the questionnaires exclusion criteria: * clinical diagnosis of dementia * terminal illness (life expectancy \< 12 months) * presence of a neurodegenerative disorder other than parkinson's disease

Keywords: parkinson's disease impulse control disorder dopamine agonist withdrawal syndrome anxiety depression healthcare utilization disability quality of life cognitive function psychosis apathy dyskinesias wearing off
tranexamic acid vs. combination with fractional carbon dioxide laser in melasma

Conditions: Melasma

Summary: the objective of this study is to assess and compare the efficacy of tranexamic acid intradermal microinjection alone versus its combination with low power fractional co2 laser in a sequential pattern. in all participants one half of the face will be randomly assigned to low power fractional co2 laser while other side to tranexamic acid intradermal microinjections on the 1st session. this split face session will be repeated every six weeks for 3 sessions. in addition, tranexamic acid intradermal microinjections will be applied for full face at the 2nd and 4th week of each split face session. the response will be evaluated by the melanin and erythema indices which will be measured using reflectance spectrophotometer, dermoscopy and photography before starting the study, two and four weeks after the last session. the sessions will take 4 months for each patient and another one month free of sessions for follow up.


Eligibility criteria:
inclusion criteria: * patients with bilateral symmetrical facial melasma exclusion criteria: * pregnancy and lactation. * patients taking oral contraceptive pills or hormonal replacement therapy at the time of the study or during the past 12 months. * concomitant use of anticoagulants. * bleeding disorders. * personal or family history of deep venous thrombosis or thromboembolic events. * scarring and keloid tendency. * active skin infection, active herpes simplex virus. * history of post-inflammatory hyperpigmentation. * history of photosensitivity or photosensitizing medication as sulfonamides tetracycline,retinoids, bleaching creams, peeling and laser two months before the study. * occupational sun exposure.

Keywords: melasma tranexamic acid fractional co2 laser
the role of sugammadex in posotoperative urinary retention in patients undergoing pelvic floor reconstructive procedures

Conditions: Postoperative Urinary Retention

Summary: the investigator will perform a single-institution randomized double-blinded controlled trial comparing intraoperative sugammadex vs. standard dose of glycopyrrolate/neostigmine combination for participants undergoing a total vaginal hysterectomy with or without pelvic organ prolapse procedures under general endotracheal anesthesia.


Eligibility criteria:
inclusion criteria: * female patients undergoing a vaginal hysterectomy with the indications of pelvic organ prolapse or abnormal uterine bleeding exclusion criteria: * patients who are already known to have voiding dysfunction * patients who have a contraindication or intolerance to any of the drugs used in the study * has a medical condition or surgical procedure that precludes reversal of neuromuscular block at the end of surgery. * has a neuromuscular disorder(s) that may affect neuromuscular block and/or trial assessments. * is dialysis-dependent or has severe renal insufficiency, defined as estimated creatinine clearance of \<30 ml/min. * has or is suspected of having a personal history or family history (parents, grandparents, or siblings) of malignant hyperthermia. * has or is suspected of having an allergy (e.g., hypersensitivity and/or anaphylactic reaction) to study treatments or its/their excipients, to opioids/opiates, muscle relaxants or their excipients, or other medication(s) used during general anesthesia. * has received or is planned to receive toremifene within 24 hours before or within 24 hours after study medication administration. * has any condition that would contraindicate the administration of study medication. * is pregnant, is attempting to become pregnant, or is lactating. * is currently participating in or has participated in an interventional clinical trial (including any other current or ongoing trial with a sugammadex treatment arm) with an investigational compound or device within 30 days of signing the informed consent form of this current trial. * male patients * patients undergoing a conventional laparoscopic or robotic approach * patients having a midurethral sling in addition to the vaginal hysterectomy * patients declining to participate in the study * patients allergic to any of the drugs used in the study (sugammadex, neostigmine and/or glycopyrrolate)
epothilone (ixabepilone) plus capecitabine versus capecitabine alone in patients with advanced breast cancer

Conditions: Cancer; Breast Cancer

Summary: the purpose of this clinical research study is to learn if bms-247550 added to the approved therapy of capecitabine (xeloda) provides measurable clinical benefits over capecitabine alone in women with metastatic breast cancer. patients should have previously received an anthracycline and a taxane. the safety of this treatment will also be studied.


Eligibility criteria:
* patients must have received prior treatment which included both an anthracycline (i.e., doxorubicin or epirubicin) and a taxane (i.e., paclitaxel or docetaxel). * patients must have received no more than two prior chemotherapy regimens. patients who have not received treatment for metastatic disease must have relapsed within one year. * patients may not have any history of brain and/or leptomeningeal metastases. * patients may not have grade 2 or worse neuropathy at the time of study entry. * patients may not have had prior treatment with any epothilones and/or capecitabine (i.e. xeloda)
a study with clevudine monotherapy or adefovir and clevudine combination in patients with chronic hepatitis b

Conditions: Chronic Hepatitis B

Summary: an open study to evaluate the efficacy, safety and sustained effect of clevudine monotherapy or adefovir and clevudine combination in proportion to roadmap concept in patients with chronic hepatitis b.


Eligibility criteria:
inclusion criteria: 1. patient is 18 years and older. 2. patient is documented to be hbsag positive for \> 6 months. 3. patient is hbv dna positive with dna levels ≥ 2,000 iu/ml within 30 days of baseline. 4. patient has alt levels \>=80 iu/l 5. patient with compensated liver disease (patient with chronic b hepatitis or liver cirrhosis \<= 6) 6. patient who is able to give written informed consent prior to study start and to comply with the study requirements. exclusion criteria: 1. patient is currently receiving antiviral, immunomodulatory, cytotoxic or corticosteroid therapy. 2. patients previously treated with interferon, peg-interferon or other immunomodulatory within the previous 6 months. 3. patients previously treated with clevudine, lamivudine, adefovir, entecavir, telbivudine or any other investigational nucleoside for hbv infection. 4. patient is coinfected with hcv, hdv or hiv. 5. patient has a history of ascites, variceal hemorrhage or hepatic encephalopathy. 6. patient with clinical evidence of decompensated liver disease or hepatocellular carcinoma 7. patient with previous liver transplantation 8. patient is pregnant or breast-feeding. 9. patient has a clinically relevant history of abuse of alcohol or drugs. 10. patient has a significant immunocompromised, gastrointestinal, renal, hematological, psychiatric, bronchopulmonary, biliary diseases excluding asymptomatic gb stone, neurological, cardiac, oncologic(except hcc)or allergic disease or medical illness that in the investigator's opinion might interfere with therapy. 11. patient has creatinine clearance less than 60ml/min as estimated by the following formula: (140-age in years) (body weight \[kg\])/(72) (serum creatinine \[mg/dl\]) \[note: multiply estimates by 0.85 for women\]
skin prick tests with allert in subjects allergic to birch pollen

Conditions: Allergic Rhinitis

Summary: assessment of skin reactivity by skin prick tests to synthetic peptides derived from the major birch allergen bet v 1, in subjects allergic to birch pollen.

the study tested - all by skin tests - in the same group of 20 trial subjects, one positive control (histamine solution), one negative control (placebo saline) and five experimental peptides called t1, t2, t3, t4 and t5. results of the skin prick tests were scored as negative (no reaction) or positive (wheal diameter \> 4 mm with erythema)

Eligibility criteria:
inclusion criteria: * history of allergy symptoms during previous birch pollen season * positive skin prick test to birch pollen extract exclusion criteria: * pregnancy * uncontrolled asthma * other significant clinical conditions or immune disorders * subjects taking antihistamines or drugs with antihistamine activity

Keywords: allergy birch
quality of life and functional performance in children with spastic cerebral palsy

Conditions: Evaluations

Summary: caregiver burden (cb) is expressed as a multidimensional response related to caregiving, including physical, psychological, emotional, social, and economic problems and has been identified as a public health concern. all these factors negatively affect caregiver health and indirectly affect the care of the disabled child .to provide better support for parents of children with cp, we must understand the difficulties faced those parents and identify the key and common areas where assistance can be rendered.

the symptoms of cp vary from person to person. a person with severe cp might need to use special equipment to be able to walk, or might not be able to walk at all and might need lifelong care. a person with mild cp, on the other hand, might walk a little awkwardly, but might not need any special help. cp does not get worse over time, though the exact symptoms can change over a person's lifetime.

Eligibility criteria:
inclusion criteria: * age older then 18 years. * there bmi will be ranged from 18.5 too 24.9 kg/m2 (misra et al., 2009) . * they are the main caregiver for there children. * they are of low or middle socioeconomic status according too socioeconomic status scale (el-gilany et al., 2012). * having at least 7months of experience in taking care of the child. * they have no congenital spinal anomalies or lower limb deformities. exclusion criteria: * children wif congenital anomalies and chromosomal disease. * children wif recent musculoskeletal surgery. * any associated problems.
the interest of the xylocaine® and ketamine on the management of acute and chronic ain after colectomy by laparoscopy

Conditions: Pain, Postoperative

Summary: recent clinical studies in abdominal surgery have shown that the use of xylocaine® parenterally intraoperative at plasma concentrations below the toxic threshold of 5 .mu.g / ml, had an analgesic effect and decreased postoperative morphine consumption. this study aims to evaluate the activity of xylocaine® and ketamine separately administered parenterally, in terms of postoperative morphine consumption and decrease incidences of postoperative chronic pain at 3 and 6 months after laparoscopic colectomy compared the placebo group. the evaluation of the intensity of postoperative pain, hyperalgesia perished skin surface scarring) and pain perception threshold by pain matcher® confirm or not the predictive nature of these criteria in the occurrence of chronic pain.


Eligibility criteria:
inclusion criteria: * surgery: segmental or total colectomy performed by laparoscopy * anesthesia state 1 and 3 exclusion criteria: * patients classified anesthesia state 4 or 5 * allergy or intolerance to any of the products used in the protocol * creatinine clearance calculated by the cockcroft formula below 50 ml / min * hepatocellular insufficiency * severe heart failure * peptic ulcer * chronic inflammatory bowel disease (ibd) * previous history of epilepsy or seizures * surgery emergency, palliative surgery, revision surgery * chronic pain requiring regular intake of analgesics include opioids * patients treated with lidocaine patch * psychic disorder * additive conduct vis-à-vis alcohol or mind-altering substances * pregnant or breastfeeding women

Keywords: postoperative analgesia painmatcher
aristolochic acid-dna adduct in urothelial carcinoma in taiwan

Conditions: Urothelial Carcinoma

Summary: to study the association between aristolochic acid and urothelial carcinoma in taiwan


Eligibility criteria:
inclusion criteria: * the resected kidney tissue in the tissue bank exclusion criteria: * the patients who had been ever exposed to arsenics, rubber, chemicals, irradiation for pelvis, or received chemotherapy.

Keywords: urothelial carinoma aristolochic acid dna adduct
microrna as biomarkers for development of metabolic syndrome in women with polycystic ovary syndrome

Conditions: Polycystic Ovary Syndrome; Insulin Resistance

Summary: the aim of this study is to explore the microrna profile in serum of women with polycystic ovary syndrome and investigate the correlation between the microrna profile and markers of metabolic syndrome.

the study consist of 2 parts: 1. a cross-sectional study of a cohort of women with pcos with analysis of materials from the established biobank. (the picolo cohort) data and blood samples from 266 women with pcos was collected from january 2010 - february 2013 as a part of the picolo collaboration: "pcos, infertility, cardiovascular and obstetric risk markers and long-term outcome" at holbaek fertility clinic and at herlev hospital. serum samples will be analysed with reverse transcript polymerase chain reaction (rt-qpcr) for selected micrornas. 2. a follow-up study of local participants from the picolo study. 90 of the participants were recruited at holbaek fertility clinic. following tests will be performed at reexamination, in order to describe the clinical phenotype: health interview, anthropometrics, acne score, ferriman-gallway score, blood pressure, transvaginal ultrasound of uterus and ovaries, insulin resistance (ir) assessed with oral glucose tolerance test (ogtt), venous blood for hormone analysis and lipid status. microrna analysis with taqman microrna array will be performed on serum samples. detection and treatment of women with pcos is a challenge due to the variability of the syndrome. if mirna could serve as marker of metabolic syndrome, it would be possible to detect and follow the women of greater risk at an earlier stage, and thereby preventing morbidity.

Eligibility criteria:
inclusion criteria: * women between 18 and 40 years when included in the picolo study * pcos based on the rotterdam 2003 consensus criteria exclusion criteria: * contraceptive pills within 8 weeks from examination, * endocrinological disease (i.e. type 1 diabetes thyroid dysfunction), * severe endometriosis (stage iii and iv) * premature ovarian insufficiency, * breastfeeding women and * pregnancy.
comparing electrical impedance tomography to computed tomographic angiography

Conditions: Pulmonary Embolism

Summary: the study aim is to determine whether electrical impedance tomography (eit) is equivalent in the detection of pulmomary emboli compared to computed tomographic angiography (cta). eit is a non-invasive, non-ionizing functional imaging technique that can be performed at bedside. electrical impedance tomography data will be collected on individuals undergoing a cta scan of the chest at medical center of the rockies (mcr). the primary outcome measure is to assess whether assessment by cta corresponds with eit in detection of pulmonary emboli. the study will include up to 63 participants. eit data will be collected for up to 20 minutes during tidal breathing and for approximately five to ten seconds during breath-holding.


Eligibility criteria:
inclusion criteria: * 18 years of age or older * undergoing a cta of the chest at mcr exclusion criteria: * under 18 years of age * body mass index (bmi) \> 30 * individuals with known thoracic metal implants or devices, such as pacemakers (internal and external), staples, or spinal and rib hardware * individuals deemed by the research team as too unstable to safely apply the eit belt, such as hemodynamic or respiratory instability (e.g., intubated patients), and individuals with unstable spinal injuries * open wounds at the site of electrode belt application